Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

29 May 2009

Half-body irradiation: a safe and acceptable treatment

Leszek MiszczykABCDEF, Aleksandra GaborekAB, Andrzej TukiendorfC, Bozena JochymekB, Jerzy WydmanskiA

Med Sci Monit 2009; 15(6): CR319-324 :: ID: 869682

Abstract

Background
The aim of this study was an evaluation of the acute toxicity of single-fraction half-body irradiation (HBI).
Material and Method
The material comprised 92 patients. Upper, lower, and middle HBI (UHBI, LHBI, MHBI) were performed in 34, 49, and 9 cases, respectively, with 6 Gy delivered for UHBI, 8 Gy for LHBI, and 6 or 8 Gy for MHBI. The patients' weights were measured on the HBI day. Two weeks later their weights and blood parameters were checked and diarrhea, skin toxicity (scale: 0-4), and nausea and vomiting intensity (scale: 0-3) were evaluated using WHO Toxicity Criteria. Items of all the evaluated symptoms were summarized and the means of the sums were calculated.
Results
Mean weight loss after HBI was 0.7 kg. One patient had grade 4 toxicity (thrombopenia). Grade 3 toxicity appeared in 9 cases (nausea and vomiting in 5, leukopenia in 1, and thrombopenia in 3). None had radiation pneumonitis. The means of the summarized items were 1.9 for UHBI than 1.4 for LHBI. The means of the summarized items were 1.6 for 8 Gy and 1.8 for 6 Gy. UHBI provoked a higher incidence and intensity of nausea and vomiting and LHBI caused a higher incidence and intensity of diarrhea. The remaining evaluated symptoms of toxicity were similar for irradiations of both halves of the body.
Conclusions
From these results one can conclude that single-dose (6-8 Gy) HBI is a safe treatment, causing a low percentage of low-level, patient-acceptable adverse radiation sequels.

Keywords: Hemibody Irradiation - methods, Aged, 80 and over, Neoplasms - radiotherapy, Safety

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750